Patents by Inventor Amir Jafri

Amir Jafri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240077312
    Abstract: Systems and methods disclosed herein include a device with a bulk acoustic wave resonator and one or more trenches that are configured to impede the flow of acoustic energy to the bulk acoustic wave resonator.
    Type: Application
    Filed: September 7, 2022
    Publication date: March 7, 2024
    Inventors: Diego EMILIO SERRANO, Sagnik PAL, Amir RAHAFROOZ, Thomas Kieran NUNAN, Ijaz JAFRI
  • Publication number: 20240034797
    Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.
    Type: Application
    Filed: October 6, 2023
    Publication date: February 1, 2024
    Inventors: Thomas Emanuel ICHIM, Steven Francis JOSEPHS, Stephen Michael PRINCE, Amir JAFRI, Robert SEGAL, David L. SCHLOTTERBECK
  • Patent number: 11814430
    Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: November 14, 2023
    Assignee: IMMUNICOM, INC.
    Inventors: Thomas Emanuel Ichim, Steven Francis Josephs, Stephen Michael Prince, Amir Jafri, Robert Segal, David L. Schlotterbeck
  • Publication number: 20230137154
    Abstract: A column for removal of a component from a fluid is disclosed. The column has a compartment with a cross sectional area. The compartment contains beads having a diameter. A ligand selected to bind to the component is coupled to the beads. The cross-sectional area and bead diameter are selected to maintain a flow velocity of the fluid within the compartment below a first threshold, thereby reducing leaching of the ligand into the fluid. Also described herein is an adsorbent comprising a ligand that is attached to a substrate by an amine bond, wherein the ligand is resistant to dissociation from the substrate.
    Type: Application
    Filed: August 9, 2022
    Publication date: May 4, 2023
    Inventors: Steven JOSEPHS, Amir JAFRI, Mark RAPTIS
  • Patent number: 11458236
    Abstract: A column for removal of a component from a fluid is disclosed. The column has a compartment with a cross sectional area. The compartment contains beads having a diameter. A ligand selected to bind to the component is coupled to the beads. The cross-sectional area and bead diameter are selected to maintain a flow velocity of the fluid within the compartment below a first threshold, thereby reducing leaching of the ligand into the fluid. Also described herein is an adsorbent comprising a ligand that is attached to a substrate by an amine bond, wherein the ligand is resistant to dissociation from the substrate.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: October 4, 2022
    Assignee: IMMUNICOM, INC.
    Inventors: Steven Josephs, Amir Jafri, Mark Raptis
  • Publication number: 20220288294
    Abstract: The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNF?. The system and method are useful for the treatment of different cancer types, stages and severity.
    Type: Application
    Filed: May 25, 2022
    Publication date: September 15, 2022
    Inventors: Steven JOSEPHS, Matthew ONG, Amir JAFRI, Robert SEGAL, Stephen PRINCE
  • Publication number: 20220265913
    Abstract: The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNF?. The system and method are useful for the treatment of different cancer types, stages and severity.
    Type: Application
    Filed: May 5, 2022
    Publication date: August 25, 2022
    Inventors: Steven JOSEPHS, Matthew ONG, Amir JAFRI, Robert SEGAL, Stephen PRINCE
  • Publication number: 20220249023
    Abstract: A vital-signs patch for a patient monitoring system that includes a housing containing a sensor that makes physiological measurements of a patient, a transmitter, a receiver, a memory, and a processor. The processor periodically takes a measurement from the sensor, converts the measurement to a data record, and stores the data record in the memory. Upon receipt of a signal from another device, the processor retrieves at least a portion of the data record, converts the retrieved portion of the data record to a vital-sign signal, and causes the transmitter to transmit the vital-sign signal to the other device.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 11, 2022
    Inventors: Mark RAPTIS, Amir JAFRI, Ganesh KATHIRESAN, Alison BURDETT
  • Publication number: 20220249363
    Abstract: Disclosed are means, methods and compositions of matter useful for amplification of adaptive immune responses towards neoplastic tissue. In one embodiment, immunization of a patient is performed by a means comprising of administering either an exogenous vaccine or stimulation of immunogenicity of the tumor so as to cause release of antigens/increased exposure of antigens, thus resulting in an “endogenous” vaccine. Subsequent to vaccination a patient is treated by an immunopheresis procedure, in order to allow for removal of “blocking factors” produced by the tumor or produced by cells programmed by tumors to produce said blocking factors. In one embodiment further immunization is performed subsequent to removal of said blocking factors in order to allow for enhancement of adaptive immune responses.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 11, 2022
    Applicant: IMMUNICOM, INC.
    Inventors: Thomas ICHIM, Amir JAFRI, Steven F. JOSEPHS
  • Publication number: 20220126272
    Abstract: A column for removal of a component from a fluid is disclosed. The column has a compartment with a cross sectional area. The compartment contains beads having a diameter. A ligand selected to bind to the component is coupled to the beads. The cross-sectional area and bead diameter are selected to maintain a flow velocity of the fluid within the compartment below a first threshold, thereby reducing leaching of the ligand into the fluid. Also described herein is an adsorbent comprising a ligand that is attached to a substrate by an amine bond, wherein the ligand is resistant to dissociation from the substrate.
    Type: Application
    Filed: January 17, 2022
    Publication date: April 28, 2022
    Inventors: Steven JOSEPHS, Amir JAFRI, Mark RAPTIS
  • Patent number: 11311239
    Abstract: A vital-signs patch for a patient monitoring system that includes a housing containing a sensor that makes physiological measurements of a patient, a transmitter, a receiver, a memory, and a processor. The processor periodically takes a measurement from the sensor, converts the measurement to a data record, and stores the data record in the memory. Upon receipt of a signal from another device, the processor retrieves at least a portion of the data record, converts the retrieved portion of the data record to a vital-sign signal, and causes the transmitter to transmit the vital-sign signal to the other device.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: April 26, 2022
    Assignee: CAREFUSION 303, INC.
    Inventors: Mark Raptis, Amir Jafri, Ganesh Kathiresan, Alison Burdett
  • Publication number: 20220105251
    Abstract: A column for removal of a component from a fluid is disclosed. The column has a compartment with a cross sectional area. The compartment contains beads having a diameter. A ligand selected to bind to the component is coupled to the beads. The cross-sectional area and bead diameter are selected to maintain a flow velocity of the fluid within the compartment below a first threshold, thereby reducing leaching of the ligand into the fluid. Also described herein is an adsorbent comprising a ligand that is attached to a substrate by an amine bond, wherein the ligand is resistant to dissociation from the substrate.
    Type: Application
    Filed: July 27, 2021
    Publication date: April 7, 2022
    Inventors: Steven JOSEPHS, Amir JAFRI, Mark RAPTIS
  • Patent number: 11264131
    Abstract: A vital-signs patch for a patient monitoring system is disclosed. The patch consists of a housing that is configured to be worn on the skin of a patient. The housing contains a radio, one or more sensor interfaces, a processor, and a battery. The processor can selectably turn portions of the processor off and on and selectably turn power off and on to at least a portion of the sensor interfaces and radio. The processor includes a timer that, each time the timer times out, will turn all the parts of the processor on and start a new timing period. When the processor receives a signal, the processor will turn off power to at least a portion of the processor and at least a portion of the sensor interfaces.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: March 1, 2022
    Assignee: CAREFUSION 303, INC.
    Inventors: Mark Raptis, Amir Jafri, Ganesh Kathiresan, Alison Burdett, Okundu Omeni, Mathew Key
  • Publication number: 20220054726
    Abstract: The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNF?. The system and method are useful for the treatment of different cancer types, stages and severity.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: Steven JOSEPHS, Matthew ONG, Amir JAFRI, Robert SEGAL, Stephen PRINCE
  • Publication number: 20220054728
    Abstract: The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNF?. The system and method are useful for the treatment of different cancer types, stages and severity.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: Steven JOSEPHS, Matthew ONG, Amir JAFRI, Robert SEGAL, Stephen PRINCE
  • Publication number: 20220054727
    Abstract: The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNF?. The system and method are useful for the treatment of different cancer types, stages and severity.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: Steven JOSEPHS, Matthew ONG, Amir JAFRI, Robert SEGAL, Stephen PRINCE
  • Publication number: 20220054725
    Abstract: The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNF?. The system and method are useful for the treatment of different cancer types, stages and severity.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: Steven JOSEPHS, Matthew ONG, Amir JAFRI, Robert SEGAL, Stephen PRINCE
  • Publication number: 20220040088
    Abstract: Disclosed are means, methods and compositions of matter useful for amplification of adaptive immune responses towards neoplastic tissue. In one embodiment, immunization of a patient is performed by a means comprising of administering either an exogenous vaccine or stimulation of immunogenicity of the tumor so as to cause release of antigens/increased exposure of antigens, thus resulting in an “endogenous” vaccine. Subsequent to vaccination a patient is treated by an immunopheresis procedure, in order to allow for removal of “blocking factors” produced by the tumor or produced by cells programmed by tumors to produce said blocking factors.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 10, 2022
    Applicant: IMMUNICOM, INC.
    Inventors: Thomas ICHIM, Amir JAFRI, Steven F. JOSEPHS
  • Publication number: 20220040087
    Abstract: Disclosed are means, methods and compositions of matter useful for amplification of adaptive immune responses towards neoplastic tissue. In one embodiment, immunization of a patient is performed by a means comprising of administering either an exogenous vaccine or stimulation of immunogenicity of the tumor so as to cause release of antigens/increased exposure of antigens, thus resulting in an “endogenous” vaccine. Subsequent to vaccination a patient is treated by an immunopheresis procedure, in order to allow for removal of “blocking factors” produced by the tumor or produced by cells programmed by tumors to produce said blocking factors.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 10, 2022
    Applicant: IMMUNICOM, INC.
    Inventors: Thomas ICHIM, Amir JAFRI, Steven F. JOSEPHS
  • Publication number: 20220041731
    Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 10, 2022
    Applicant: IMMUNICOM, INC.
    Inventors: Thomas Emanuel ICHIM, Steven Francis JOSEPHS, Stephen Michael PRINCE, Amir JAFRI, Robert SEGAL, David L. SCHLOTTERBECK